STOCKHOLM / COPENHAGEN – Elekta (EKTA-B.ST) has evolved radiosurgery to an unprecedented level with the launch of Elekta Esprit. This latest and most advanced system will offer significantly faster automated treatment planning for clinicians, more personalized and patient-friendly treatments, and a degree of precision able to protect the mind and the person.
With a variety of innovations now available in a single platform, Esprit offers clinicians superior visualization, as well as remote accessibility and collaboration tools for the treatment team. And it provides the accuracy to treat even the most challenging targets while delivering a gentler more personalized approach to radiosurgery.
“Esprit will allow clinicians to take radiosurgery to the next level and treat patients with the highest accuracy, protecting their mind and memories and enabling a higher quality of life,” says Gustaf Salford, Elekta’s President and CEO. “Continuing the Leksell Gamma Knife tradition, Elekta yet again redefines what was thought possible in stereotactic radiosurgery.”
Esprit offers what every patient and every doctor wants: the highest precision to preserve peoples’ functions and spirit. That’s why clinicians rely on the clinically proven outcomes of Leksell Gamma Knife. With over 50 years of real-world evidence, Leksell Gamma Knife continues to lead the way in intracranial radiosurgery, relentlessly driving the standard of care forward.
“In line with Elekta’s commitment of ensuring every patient has access to the best care possible, we are developing solutions that address real clinical needs and empower clinicians to focus on patient-centric care while increasing operational efficiency,” says Verena Schiller, President of Elekta’s Neuroscience Solutions. “Esprit was built to address not only today’s clinical needs but is also poised to assimilate future developments that push the boundaries of intracranial radiosurgery treatment.”
Clinicians will appreciate Esprit’s accuracy of <0.3 mm* ; flexible workflow options based on single session, fractionated, adaptive or staged protocols; in a seamless integrated system design for end-to-end ease of use.
Esprit was unveiled at the European Society for Radiotherapy and Oncology (ESTRO) 2022 on May 6. For more information, visit https://www.elekta.com/products/stereotactic-radiosurgery/elekta-esprit/.
Elekta Esprit is pending CE submission, not available in all markets.
*Data maintained by Elekta
# # #
For further information, please contact:
Mattias Thorsson, Vice President, Head of Corporate Communications
Tel: +46 70 865 8012, e-mail: Mattias.Thorsson@elekta.com
Time zone: CET: Central European Time
Raven Canzeri, Global Director, Media Relations
Tel: +1 770-670-2524, e-mail: Raven.Canzeri@elekta.com
Time zone: ET: Eastern Time
About Elekta
As a leader in precision radiation therapy, Elekta is committed to ensuring every patient has access to the best cancer care possible. We openly collaborate with customers to advance sustainable, outcome-driven and cost-efficient solutions to meet evolving patient needs, improve lives and bring hope to everyone dealing with cancer. To us, it's personal, and our global team of 4,700 employees combine passion, science, and imagination to profoundly change cancer care. We don’t just build technology, we build hope. Elekta is headquartered in Stockholm, Sweden, with offices in more than 120 countries and listed on Nasdaq Stockholm. For more information, visit elekta.com or follow @Elekta on Twitter.